Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Soft Robotic Medical Device to Benefit Patients with Heart Failure



The blood-free pump uses compressed air to contract along with the heart’s natural rhythm and strengthen the organ’s function.

Share this!

January 23, 2017 | by Sarah Hand, M.Sc.

A soft robotic sleeve which supports contraction of the heart muscle has been developed by researchers at Harvard University and Boston Children’s Hospital. The blood-free pump uses compressed air to contract along with the heart’s natural rhythm and strengthen the organ’s function.

Patients with heart failure are often outfitted with a left ventricular assist device (LVAD), which can prologue life. Unfortunately, these medical devices carry inherent risks, such as stroke, requiring patients to be prescribed anticoagulant drugs.

In comparison, the robotic device does not come in contact with a patient’s blood, eliminating the need for blood thinners and reducing the risk of infection. The soft robotic sleeve also doesn’t produce disruptive changes in blood flow that can lead to some of the negative side effects associated with LVADs.

The medical device is composed of silicone, and the size and fit can be adjusted on an individual basis. According to the researchers – whose article was published in the journal, Science Translational Medicine – the device could benefit patients on the transplant list who are waiting for a new heart.

“The cardiac field had turned away from idea of developing heart compression instead of blood-pumping VADs due to technological limitations, but now with advancements in soft robotics it’s time to turn back,” said Dr. Frank Pigula, a cardiothoracic surgeon, and one of the authors of the study. “Most people with heart failure do still have some function left; one day the robotic sleeve may help their heart work well enough that their quality of life can be restored.”

According to the Centers for Disease Control and Prevention (CDC), approximately 5.7 million adults in the US have heart failure. Within five years of diagnosis, around 50 percent of patients with heart failure will die of the condition.

Keywords: Medical Device, Heart Failure, Anticoagulants


Share this with your colleagues!

Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News

FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News

One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


Top 5 Most Impactful Tweets in Life Sciences During the Last Week


EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider

Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology

Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn

eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials

Copyright © 2016-2017 Honeycomb Worldwide Inc.